Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Morie Gertz

Showing results (71-80 of 111) with videos related to

Pageof 12
Sort By:
Journal of Cardiac Failure|December 8, 2023
Effect of Eplontersen on Cardiac Structure and Function in Patients With Hereditary Transthyretin AmyloidosisAhmad Masri, Mathew S Maurer, Brian L Claggett, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|June 13, 2025
Hepatic involvement in light chain amyloidosis: analysis of 130 patients and predictors of hepatic response and survivalMatthew J Rees, Nadia Toumeh, Angela Dispenzieri, et al.
Journal of Neurology|August 14, 2024
Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansformIsabel Conceição, John L Berk, Markus Weiler, et al.
Journal of Neurology|February 3, 2025
Correction: Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansformIsabel Conceição, John L Berk, Markus Weiler, et al.
Cancer Research|April 6, 2007
Molecular dissection of hyperdiploid multiple myeloma by gene expression profilingWee J Chng, Shaji Kumar, Scott Vanwier, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 2, 2024
Association of Thrombocytopenia With Disease Burden, High-Risk Cytogenetics, and Survival in Newly Diagnosed Multiple Myeloma Patients Treated With Novel TherapiesCharalampos Charalampous, Utkarsh Goel, Prashant Kapoor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2010
Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemiaIrene M Ghobrial, Morie Gertz, Betsy Laplant, et al.
American Journal of Hematology|April 11, 2025
The Impact of Melphalan Conditioning and CD34 <sup>+</sup> Cell Dose and Schedule on Post-Transplant Outcomes in AL AmyloidosisEli Muchtar, Vaishali Sanchorawala, Hamza Hassan, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 18, 2026
Ixazomib, Cyclophosphamide, and Dexamethasone (ICd), With or Without Daratumumab in Relapsed Multiple MyelomaShaji Kumar, Betsy Knopf, Erik Asmus, et al.
British Journal of Haematology|May 10, 2026
Predictors of renal response in AL amyloidosis following anti-plasma cell therapy: The impact of baseline serum free light chain levels and light chain isotypeMatthew J Rees, Binoy Yohannan, Susan Geyer, et al.
Pageof 12

Showing results (71-80 of 111) with videos related to

Sort By:
Pageof 12
Journal of Cardiac Failure|December 8, 2023
Effect of Eplontersen on Cardiac Structure and Function in Patients With Hereditary Transthyretin AmyloidosisAhmad Masri, Mathew S Maurer, Brian L Claggett, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|June 13, 2025
Hepatic involvement in light chain amyloidosis: analysis of 130 patients and predictors of hepatic response and survivalMatthew J Rees, Nadia Toumeh, Angela Dispenzieri, et al.
Journal of Neurology|August 14, 2024
Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansformIsabel Conceição, John L Berk, Markus Weiler, et al.
Journal of Neurology|February 3, 2025
Correction: Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansformIsabel Conceição, John L Berk, Markus Weiler, et al.
Cancer Research|April 6, 2007
Molecular dissection of hyperdiploid multiple myeloma by gene expression profilingWee J Chng, Shaji Kumar, Scott Vanwier, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 2, 2024
Association of Thrombocytopenia With Disease Burden, High-Risk Cytogenetics, and Survival in Newly Diagnosed Multiple Myeloma Patients Treated With Novel TherapiesCharalampos Charalampous, Utkarsh Goel, Prashant Kapoor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2010
Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemiaIrene M Ghobrial, Morie Gertz, Betsy Laplant, et al.
American Journal of Hematology|April 11, 2025
The Impact of Melphalan Conditioning and CD34 <sup>+</sup> Cell Dose and Schedule on Post-Transplant Outcomes in AL AmyloidosisEli Muchtar, Vaishali Sanchorawala, Hamza Hassan, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 18, 2026
Ixazomib, Cyclophosphamide, and Dexamethasone (ICd), With or Without Daratumumab in Relapsed Multiple MyelomaShaji Kumar, Betsy Knopf, Erik Asmus, et al.
British Journal of Haematology|May 10, 2026
Predictors of renal response in AL amyloidosis following anti-plasma cell therapy: The impact of baseline serum free light chain levels and light chain isotypeMatthew J Rees, Binoy Yohannan, Susan Geyer, et al.
Pageof 12